Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

Autor: Christopher R. Garrett, Georgia Kollia, Caio Rocha-Lima, Wendy Hayes, O. Mokliatchouk, S. Ford, S. Galbraith, D. S. A. Nuyten, Jan Buter, John L. Marshall, J. M. Chemidlin, Lillian L. Siu, Anthony B. El-Khoueiry, Patricia LoRusso, Samira Syed, Linda M. Velasquez, Pierre Major, D. Feltquate

Publikováno v: Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S & Nuyten, D S A 2011, ' Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy ', British Journal of Cancer, vol. 105, no. 1, pp. 44-52 . https://doi.org/10.1038/bjc.2011.182
British Journal of Cancer, 105(1), 44-52. Nature Publishing Group
British Journal of Cancer

Background: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies. Methods: Patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3ad3b8f4d3c86d72df83acf844ea56d
https://research.vumc.nl/en/publications/bcf70cef-167e-4a6e-ac6b-8c3b5daf8a3b

Nivolumab (Anti-Programmed Death-1 [PD-1]; BMS-936558) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

Autor: D. Feltquate

Publikováno v: Annals of Oncology. 24:i7

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8eff596366e02cd99f5eb3fff51ab673
https://doi.org/10.1093/annonc/mdt042.5

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

Autor: Linda M. Velasquez, Anthony B. El-Khoueiry, Lillian L. Siu, Christopher R. Garrett, Georgia Kollia, Giuseppe Giaccone, P. He, D. Feltquate, John L. Marshall, Patricia LoRusso

Publikováno v: Journal of Clinical Oncology. 25:14018-14018

14018 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Prior studies have validated both VEGF and EGF signaling pathways as targets in AGM. The MTD of single-agent brivanib is 800 mg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f726685706b7dc1b7e9c92d8f91110c
https://doi.org/10.1200/jco.2007.25.18_suppl.14018

Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases

Autor: S. Galbraith, S. Luroe, D. Feltquate, Derek J. Jonker, Linda M. Velasquez, Gordon C Jayson, J. Kelsey, O. Mokliatchouk, L. S. Rosen, S. Platero

Publikováno v: ResearcherID

3506 Background: Many tumors express the FGFR ligand FGF2, and increased levels of FGF are correlated with poor prognosis in pts with RCC, HCC, NSCLC, esophageal, and pancreatic cancer. Brivanib is...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897cc4566784bec8b6458194d9cb7bc9
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000208457400864&KeyUID=WOS:000208457400864